In addition, combined therapies comprising ibrutinib and anti-CD19 CAR-T cells in patients with CLL after ibrutinib failure are considered feasible and safe and have already been studied (NCT05020392). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.